Lots of interesting abstracts and cases were submitted for TCTAP 2024. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-017
Ten-Year Clinical Outcomes According to Atherosclerotic Cardiovascular Disease Risk Score From AHA/ACC in Korean Patients With Significant Coronary Artery Spasm
By Woo Jin Ahn, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Jinah Cha, Sujin Hyun, Jaeho Kang, Wonsang Chu, Soohyung Park, Cheol Ung Choi
Presenter
Sujin Hyun
Authors
Woo Jin Ahn1, Seung-Woon Rha2, Byoung Geol Choi2, Se Yeon Choi2, Jae Kyeong Byun2, Jinah Cha2, Sujin Hyun2, Jaeho Kang2, Wonsang Chu2, Soohyung Park2, Cheol Ung Choi2
Affiliation
Tongyeong Detention Center, Korea Correctional Service, Ministry of Justice, Korea (Republic of)1, Korea University Guro Hospital, Korea (Republic of)2
View Study Report
TCTAP A-017
Angiography/QCA
Ten-Year Clinical Outcomes According to Atherosclerotic Cardiovascular Disease Risk Score From AHA/ACC in Korean Patients With Significant Coronary Artery Spasm
Woo Jin Ahn1, Seung-Woon Rha2, Byoung Geol Choi2, Se Yeon Choi2, Jae Kyeong Byun2, Jinah Cha2, Sujin Hyun2, Jaeho Kang2, Wonsang Chu2, Soohyung Park2, Cheol Ung Choi2
Tongyeong Detention Center, Korea Correctional Service, Ministry of Justice, Korea (Republic of)1, Korea University Guro Hospital, Korea (Republic of)2
Background
Atherosclerotic cardiovascular disease (ASCVD) risk score is a well-known risk stratification tool for assessing cardiovascular events. However, validation studies of 10-year ASCVD risk score predicting clinical outcomes in Korean patients, especially in vasospastic angina are limited.
Methods
A total of 3,991 patients with vasospastic angina, documented by the acetylcholine (ACH) or ergonovine (ERG) provocation test. Patients were divided into four groups, based on the ASCVD risk score: <5.0% group (AS1, n=1,315), 5.0 % to 9,9% group (AS2, n=937), 10.0% to 19.9% group (AS3, n=1,079) and ≧20% group (AS4, n=660). The primary endpoint was major adverse cerebral and cardiovascular event 1 (MACCE 1), including stroke and major adverse cardiovascular event (MACE). The secondary endpoint was MACCE 2, defined as composite of MACE and recurrent angina requiring follow-up coronary angiography (CAG).
Results
10-year ASCVD risk score was well stratified from AS1 to AS4 by 1.9%, 7.4%, 14.0%, and 30.5%, respectively (P<0.001). Baseline characteristics were also well stratified, presenting worse clinical profile in AS4 than in AS1. From AS1 to AS4, increasing severity of insignificant coronary stenosis (<70%) (AS1: 45.9%, AS2: 55.2%, AS3: 63.9%, AS4: 69.4%, P<0.001) was observed. Increasing incidence of both MACCE1 and MACCE2 was demonstrated through AS1 to AS4 (MACCE1: 6.6%, 6.9%, 9.6%, 17.6%, P<0.001; MACCE2: 25.3%, 25.2%, 27.8% 36.6%, P<0.001) including stroke (3.8%, 4.3%, 7.5%, 9.5%, P<0.001) and recurrent angina (21.7%, 21.7%, 22.1%, 28.5%, P=0.022).
Conclusion
The 10-year ASCVD risk score, in addition to stratifying severity of insignificant coronary stenosis, was associated with higher risk of MACCE1 and MACCE2 in patients with significant CAS.
